Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010421 | 1.00 | MEN1 (0.50) | MEN1KMT2AFDPSSMPD1GGPS1 | |
| SCHEMBL7919934 | 0.78 | MEN1 (0.36) | MEN1KMT2AFDPSSMPD1GGPS1 | |
| SCHEMBL22021840 | 0.75 | GGPS1 (0.35) | MEN1KMT2AFDPSSMPD1GGPS1 | |
| SCHEMBL22666450 | 0.75 | GGPS1 (0.35) | MEN1KMT2AFDPSSMPD1GGPS1 | |
| SCHEMBL25766806 | 0.75 | GGPS1 (0.35) | MEN1KMT2AFDPSSMPD1GGPS1 | |
| SCHEMBL22951430 | 0.74 | FDPS (0.33) | FDPSSMPD1GGPS1CES2 | |
| SCHEMBL10384653 | 0.70 | GGPS1 (0.46) | FDPSSMPD1GGPS1 | |
| SCHEMBL24793822 | 0.70 | GGPS1 (0.46) | FDPSSMPD1GGPS1 | |
| SCHEMBL10384529 | 0.70 | GGPS1 (0.46) | FDPSSMPD1GGPS1 | |
| SCHEMBL8771494 | 0.70 | GGPS1 (0.46) | FDPSSMPD1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135612-A1 | MODIFIED NUCLEOSIDE AND SYNTHETIC METHODS THEREOF | Stemirna Therapeutics Co., Ltd. (CN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135612-A1 | MODIFIED NUCLEOSIDE AND SYNTHETIC METHODS THEREOF | RNMT, NSUN2, RNGTT | MEN1 3596/4885KMT2A 1219/4885FDPS 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.